Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?
Michael A Liu, Kyle Miyazaki, Karie Runcie, Hanna Cash, Lingbin Meng · 2026
Read Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? by Michael A Liu, Kyle Miyazaki, Karie Runcie, Hanna Cash, Lingbin Meng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13427791.txt.
Description
Michael A Liu and colleagues ask whether the site of spread should steer first treatment for metastatic clear cell kidney cancer. Frontline choices now pair immune drugs together or pair an immune drug with a vessel-blocking drug, usually chosen by tumour type and risk group.
Trial sub-analyses and real-world centre data hint that bone spread may blunt immune attack and raise vessel-growth signals, which could favour the immune-plus-vessel-blocking pair in bone-heavy disease. Liver spread may show a similar site pattern. The paper frames a biology-led guess that trials must test, not a rule for clinics yet.
Catalog record
| CREATOR | Michael A Liu, Kyle Miyazaki, Karie Runcie, Hanna Cash, Lingbin Meng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |